Diagnostic competence of mir-375 and mir-93-5p serum levels in malignant and non-malignant prostate diseases

Yükleniyor...
Küçük Resim

Tarih

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

Erişim Hakkı

info:eu-repo/semantics/openAccess

Özet

Introduction: The study purpose is to examine the diagnostic competence of miR-375 and miR-93-5p serum levels in prostate cancer differential diagnosis. It is also aimed to examine whether there is an interfering situation in the differentiation of chronic prostatitis, benign prostatic hyperplasia (BPH) and prostate cancer, considering the oncogenic and tumor suppressor properties of miRNAs together with the proinflammatory characteristics. Materials and Methods: 25 Patients with BPH, 10 patients with chronic prostatitis and 33 patients with prostate cancer were included in the study. RNA isolation, cDNA synthesis and qRT-PCR steps were performed with Qiagen branded kits based on SYBR Green method, using the protocol of the commercial company. For statistical analysis, -ΔCt values, obtained from the use of ce-miR-39 Ct values in normalization, were used. Differences between groups were tested by independent sample t test and variance analysis. ROC analysis was performed to calculate the diagnostic competence. "Fold change" calculations were performed online on Qiagen webpage. In all analyzes, alpha error level was accepted as 0.05. Results: The results are summarized in Table-1. Conclusions:It was observed that miR-375 and miR-93-5p differ in significantly between malignant and non-malignant disease groups. It was assessed that the sensitivity of miR-375 to differentiate non-malignant diseases from malignant diseases was higher than prostate specific antigen (PSA) and chronic prostatitis may be an interfering condition in BPH and cancer differential diagnosis

Açıklama

Anahtar Kelimeler

Kaynak

European Human Genetics Conference

WoS Q Değeri

Scopus Q Değeri

Cilt

Sayı

Künye

Y. DULGEROGLU, O EROGLU (2018). Diagnostic competence of mir-375 and mir-93-5p serum levels in malignant and non-malignant prostate diseases. European Human Genetics Conference.

Onay

İnceleme

Ekleyen

Referans Veren